-
CCT007093: PPM1D Inhibitor Workflows
2026-09-30
CCT007093 enables mechanism-focused studies of PPM1D, P38 kinase activation, and context-dependent cell injury. Its strongest use case is a paired workflow that combines target inhibition, time-resolved signaling, viability testing, and pharmacological rescue in cancer or inflammatory kidney models.
-
MK-2206 Dihydrochloride: Akt Assay Workflows
2026-09-30
MK-2206 dihydrochloride provides a selective way to test whether Akt signaling drives infection-associated immune evasion, cancer cell apoptosis, or pathway-dependent drug responses. This guide translates the reference study into practical controls, dose-timing experiments, and troubleshooting steps for reproducible PI3K/Akt/mTOR research.
-
Magnetic Exosome Hydrogel Activates Repair in DBD
2026-09-29
A 2026 study developed a magnetic chitosan nanoparticle–exosome hydrogel that improved bladder function in a diabetic bladder dysfunction rat model. Its findings connect defocused low-energy shock wave activation of adipose-derived stromal cell exosomes with the FAK–p38 MAPK–GATA4 pathway, enhanced VEGF and NGF signaling, and coordinated vascular and neural repair.
-
Chlorpromazine HCl as an Endocytosis Probe
2026-09-29
Chlorpromazine HCl is more than a dopamine receptor antagonist: it can serve as a mechanistic perturbation tool when interpreted alongside orthogonal endocytosis and viability assays. This guide connects receptor pharmacology, neuronal signaling, and Spiroplasma entry biology while defining what chlorpromazine-based evidence can—and cannot—prove.
-
Methyl-β-cyclodextrin: Membrane Workflow Guide
2026-09-28
Methyl-β-cyclodextrin (MβCD) supports controlled membrane cholesterol extraction for experiments on membrane organization, fluidity, and cholesterol-dependent signaling. Use it in research workflows only; treatment conditions must be optimized for each cell model, and prepared solutions should be used promptly rather than stored long term.
-
Hepatic sEH, Nrf2, and Osteoporosis Redox Biology
2026-09-27
A study in Free Radical Biology and Medicine links hepatic soluble epoxide hydrolase (sEH) to osteoclast differentiation through changes in circulating lipid mediators, inflammation, and Nrf2–ARE signaling. Its clinical, mouse, and cell-based evidence supports a liver–bone regulatory axis, while leaving important questions about causality, clinical relevance, and therapeutic translation open.
-
Lanabecestat (AZD3293): Evidence and Research Use
2026-09-26
Lanabecestat (AZD3293) is a supplier-described, blood-brain barrier-penetrant BACE1 inhibitor for Alzheimer's disease research. In cultured rat cortical neurons, low-dose BACE inhibitor treatment that reduced amyloid-beta secretion by less than 50% did not reduce synaptic transmission in the conditions tested; this is a preclinical finding, not evidence of clinical benefit.
-
From Replication Stress to Mitotic Targeting
2026-09-26
Translational oncology increasingly depends on understanding how distinct cell-cycle stresses shape tumor response. This article connects evidence on transcription termination after WEE1 inhibition with the separate mitotic mechanism of TAI-1, outlining a disciplined strategy for evaluating Hec1 inhibition without treating these pathways as interchangeable.
-
Cholesterol in LNP Assays: Separating Formulation from Biolo
2026-09-25
Cholesterol can shape lipid nanoparticle performance, but a delivery result does not by itself reveal what cholesterol contributed. This article uses the 2026 intravesical p21 mRNA study to show how to separate formulation effects from therapeutic biology in bladder cancer assays.
-
Paclitaxel (Taxol) Workflows for Cancer Research
2026-09-25
Build a mechanistically grounded Paclitaxel workflow that links dose selection to microtubule disruption, cell-cycle profiling, and phenotype-specific controls. Practical guidance covers stock handling, assay design, and how to distinguish Taxol effects from the DNA-damage mechanism discussed in the historical topotecan review.
-
BRD4770: G9a Histone Methyltransferase Inhibitor
2026-09-24
BRD4770 is a G9a histone methyltransferase inhibitor reported to reduce intracellular H3K9 di- and trimethylation and inhibit proliferation in PANC-1 cells. This research-use compound provides a tool for studying epigenetic regulation, but its reported activity should not be conflated with the separate BRD4–RAC1 breast-cancer study.
-
Romidepsin (FK228): From Chromatin to Translation
2026-09-24
Romidepsin (FK228) gives translational researchers a focused way to perturb class I HDAC activity and study how chromatin regulation connects to cancer-cell phenotypes. This article pairs its mechanistic rationale and practical use with a proteomics-led NSCLC study, while making clear what that cross-domain comparison can—and cannot—tell us.
-
(-)-Epigallocatechin gallate (EGCG) Research Guide
2026-09-23
(-)-Epigallocatechin gallate (EGCG) is a major green tea catechin used in apoptosis, antiviral research, antiangiogenic, and cancer chemoprevention studies. Its experimental value depends on formulation, exposure conditions, and whether it is tested as free EGCG or as a component of a delivery platform.
-
Dyngo-4a for Reliable Endocytosis Assays
2026-09-23
Learn how Dyngo-4a (SKU B5997) can help researchers distinguish dynamin-dependent trafficking effects from genuine cytotoxicity in viability, proliferation, and lipid nanoparticle workflows. This scenario-based guide covers mechanism, controls, dose selection, interpretation, and practical product-selection criteria.
-
Sulfamonomethoxine: From DHPS to Translation
2026-09-22
Sulfamonomethoxine is more than a veterinary antimicrobial benchmark: its DHPS mechanism, formulation constraints, pharmacokinetic context, and environmental fate create a practical framework for translational research. This article connects SMM efficacy studies with residue assessment, aquatic safety, and biotransformation strategy.